These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28038962)

  • 1. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
    J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Svensson EM; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6406-12. PubMed ID: 25114140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
    van Heeswijk RP; Dannemann B; Hoetelmans RM
    J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.
    Svensson EM; Dosne AG; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):682-691. PubMed ID: 27863179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
    Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
    Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
    Dailly E; Reliquet V; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2005 Apr; 61(2):153-6. PubMed ID: 15761750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.